187P Ipatasertib and atezolizumab in cancers with increased PI3K-AKT pathway activity: First results from the CRAFT trial

187P Ipatasertib and atezolizumab in cancers with increased PI3K-AKT pathway activity: First results from the CRAFT trial

Saved in:
Bibliographic Details
Published in:Annals of oncology Vol. 34; pp. S256 - S257
Main Authors: Heilig, C.E., Singh, M., Teleanu, M-V., Desuki, A., Kindler, T., Bitzer, M., Baier, B.D., Kunzmann, V., von Bubnoff, N., Süsse, H., Heiligenthal, L., Steindorf, K., Benner, A., Kreutzfeldt, S., Heining, C., Horak, P., Hübschmann, D., Glimm, H., Fröhling, S., Schlenk, R.F.
Format: Journal Article
Language:English
Published: Elsevier Ltd 01-10-2023
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
ISSN:0923-7534
1569-8041
DOI:10.1016/j.annonc.2023.09.2911